Step Pharma

High-Level Overview

Step Pharma is a clinical-stage biotechnology company developing first-in-class oral inhibitors of cytidine triphosphate synthase 1 (CTPS1), an enzyme essential for nucleotide synthesis in rapidly proliferating cells. Their lead candidate, dencatistat (STP938), targets blood cancers like lymphoma and essential thrombocythaemia, solid tumors such as ovarian cancer, and has potential expansion into autoimmune diseases, selectively killing cancer cells while sparing healthy ones.[1][2][4][5] Headquartered in Saint-Genis-Pouilly, France, the company serves oncology patients and physicians by addressing unmet needs in targeted cancer therapies, with recent momentum from €38 million Series C financing, IND approvals, and clinical trial initiations across multiple indications.[2][4][7]

Origin Story

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery, building on scientific breakthroughs by Prof. Alain Fischer and Dr. Sylvain Latour from Inserm's UMR1163 unit, who identified CTPS1 as a target in immune disorders with oncology potential.[3][6][7] The idea emerged from research on CTPS1's role in T-cell proliferation, initially for autoimmune diseases, but pivoted to cancer due to its selective toxicity in malignant cells.[3][6] Key early milestones include a €14.5M raise for autoimmune work, €35M Series B in 2021, STP938's CTA/IND approval for lymphoma in 2022, synthetic lethality discoveries in 2023, and solid tumor IND in 2024, culminating in the recent Series C led by V-Bio Ventures.[2][3][7]

Core Differentiators

• Pipeline-in-a-Product Strategy: Dencatistat (STP938) is a single, orally bioavailable CTPS1 inhibitor with broad potential across lymphoma, ovarian cancer, essential thrombocythaemia, and beyond, enabling efficient multi-indication development.[1][2][4][7]
• High Selectivity and Safety: Targets CTPS1 to disrupt nucleotide synthesis in cancer cells (overexpressed CTPS1 or CTPS2-loss contexts) while healthy cells rely on CTPS2, minimizing side effects compared to broad immunosuppressants.[1][2][3][5]
• Experienced Leadership: Team with 50+ years in oncology drug development, recently bolstered by CMO Karen L. Smith (MD, PhD, MBA, LLM), driving rapid clinic advancement.[2][4][6]
• Strong Funding and Network: Backed by syndicate including V-Bio Ventures, Hadean Ventures, Sunstone Life Science Ventures, Pontifax, and Kurma Partners, with awards like "First-in-class therapeutic innovation" in 2021.[2][3][7]

Role in the Broader Tech Landscape

Step Pharma rides the wave of precision oncology, leveraging synthetic lethality (e.g., CTPS2 loss in solid tumors) and nucleotide synthesis inhibition trends, akin to approved therapies like venetoclax but with oral CTPS1 specificity.[2][3][5] Timing aligns with surging demand for targeted agents post-immunotherapy era, as market forces favor multi-indication assets amid rising cancer incidence and resistance challenges; their "pipeline-in-a-product" derisks development amid biotech funding constraints.[4][7] By pioneering CTPS1 inhibition, they influence the ecosystem through collaborations with academic centers and big pharma, potentially expanding to autoimmune applications and setting a model for enzyme-targeted proliferation blockers.[3][5][6]

Quick Take & Future Outlook

Step Pharma is poised for proof-of-concept data from ongoing Phase II lymphoma trials (potential accelerated approval) and solid tumor/ET studies, with Series C funds fueling expansion.[1][2][7] Trends like AI-driven target validation and combination regimens with PD-1 inhibitors will shape progress, evolving their influence from niche CTPS1 leader to backbone therapy provider across oncology and immunology.[4][5] As dencatistat advances, expect partnerships or buyouts, redefining selective cancer treatment much like their founding vision promised—a step change for patients.